media – Page 50 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Sino Biopharmaceutical’s subsidiary’s innovative drug LM-302 has been included in the Breakthrough Therapy Program

On August 19, Sino Biopharmaceutical (01177) issued an announcement, announcing that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., independently developed an innovative drug.LM-302 (CLDN18.2ADC) has been included in the Breakthrough Therapy Designation program by the Center for Drug Evaluation of the China National Medical Products Administration for the first-line treatment of CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma in combination with a PD-1 monoclonal antibody. LM-302 is a potential first-in-class antibody-drug conjugate targeting CLDN18.2. Clinical studies have demonstrated an objective response rate (ORR) of 65.9% and a disease control rate (DCR) of 85.4% in 41 evaluable patients. For 32 patients with CLDN18.2 ≥ 25%, the ORR was 71.9% and the DCR was 96.9%. This drug is currently undergoing a Phase III clinical trial in China. Its inclusion in the Breakthrough Therapy program is expected to accelerate its market launch, providing an innovative treatment option for ...
- Source: drugdu
- 110
- August 21, 2025
Interphex

Organiser: American Pharmacists Association Time：April 21 – April 23, 2026 address：655 West 34th Street, New York, NY 10001-1188, USA Exhibition hall：Javits Convention Center, NYC Product range: Active Pharmaceutical Ingredients (APIs): Western medicine raw materials such as vitamins, hormones, cephalosporins, macrolides, and central nervous system drugs Excipients and Dosage Forms: Excipients, fluids, enteric coatings, antioxidants, sweeteners, permeation enhancers, preservatives, disintegrants, clarifying agents, pH regulators, etc. Natural Extracts: Plant extracts, animal extracts, dietary fibers, and cosmetic raw materials About Interphex： The Interphex in New York, USA, is a globally leading pharmaceutical and biotechnology event that integrates industry innovation with expert-led conferences. Since its inception in 1979, it has been the most trusted life sciences exhibition in North America, spanning both the chemical pharmaceutical and biopharmaceutical sectors. Exhibitors have the opportunity to meet decision-making buyers from top global pharmaceutical companies through this event.
- Source: drugdu
- 233
- August 21, 2025
After the impact of centralized procurement, this old pharmaceutical company gambled heavily on research and development

When the heavy hammer of national centralized procurement hit the core products, Fudan Zhangjiang’s revenue and net profit were both under pressure. Recently, Fudan Zhangjiang released its 2025 semi-annual report: achieving revenue of 390 million yuan, a year-on-year decrease of 4.42%; The net profit attributable to the parent was 5.7151 million yuan, a year-on-year decrease of 91.89%. However, the company still maintains high R&D investment, focusing on the two major technical fields of photodynamic drugs and ADC, and preparing chips for future comebacks. The financial report shows that Fudan Zhangjiang invested a total of 178 million yuan in R&D in the first half of 2025, a year-on-year increase of 14.58%, accounting for 45.63% of revenue, a year-on-year increase of 7.57 percentage points. Impact of centralized procurement: 35% price reduction of main products According to public information, Shanghai Fudan Zhangjiang was founded in Zhangjiang High-tech Park, Pudong, Shanghai in November 1996. ...
- Source: drugdu
- 138
- August 20, 2025
Zhifei Biological has turned from profit to loss, and the transformation and breakthrough of domestic vaccines have become a trend

The once leading player in the vaccine industry is now facing unprecedented challenges. On August 18th, the semi-annual report released by Chongqing Zhifei Biological Products Co., LTD., a leading domestic vaccine enterprise, showed that the company’s revenue was 4.919 billion yuan, a year-on-year plunge of 73.06%. Net profit plummeted sharply from a profit of 2.234 billion yuan in the same period of the previous year to a loss of 597 million yuan. From the perspective of specific products, in the first half of 2025, the batch release volume of Chongqing Zhifei Biological’s nine-valent HPV vaccine dropped by 76.8% year-on-year, from 18.2717 million doses to 4.2388 million doses. The batch release volume of the quadrivalent HPV vaccine has dropped from 466,000 doses in the same period last year to zero. The revenue from its agency of Merck’s products dropped from 17.59 billion yuan in the same period last year to 4.37 ...
- Source: drugdu
- 232
- August 20, 2025
The subsequent R&D nodes and external licensing expectations of the innovative vaccine pipeline are worth paying attention to

Citic Securities stated that the total number of batch releases in the vaccine industry in the first half of 2025 was 1,629, a year-on-year decrease of 17%. The batch release of rabies vaccine, HPV vaccine and other products increased rapidly, while the year-on-year decline of polio vaccine, meningitis vaccine, MMR vaccine and others was relatively large. In terms of research and development, several major vaccine varieties were approved for marketing in the first half of the year, such as Cansino’s PCV13 and Wantai Biological’s 9-valent HPV vaccine. There are also several products in the market review stage, such as Chifeng Biological’s PCV15 and MCV4, Kangtai Biological’s IPV and quadrivalent influenza, etc. It is expected that in the second half of 2025, the sales of some products will improve year-on-year, and the launch of new products will contribute to the increase in performance. The subsequent research and development nodes of the ...
- Source: drugdu
- 154
- August 20, 2025
Zhifei Bio’s subsidiary’s vaccine application for clinical trial accepted

On August 18, Zhifei Bio(300122) issued an announcement that the adsorbed acellular diphtheria, tetanus and pertussis (component) combined vaccine (for adults and adolescents) developed by the company’s wholly-owned subsidiary Zhifei Green Bamboo recently obtained the National Medical Products Administration’s drug clinical trial application acceptance notice. This vaccine is a combination vaccine targeting pertussis (whooping cough), diphtheria, and tetanus, and is suitable for healthy individuals aged seven years and above. Currently, no component DTP vaccine has been approved for use in adolescents and adults in China, and the market prospects are promising. The announcement noted that the acceptance of the clinical trial application for the adolescent and adult diphtheria, pertussis, and tetanus vaccine is the result of the company’s technological innovation and scientific research. If the project progresses smoothly, it will further strengthen the company’s market competitiveness, enrich its product portfolio, and enhance profitability. The company reminds investors that drug development ...
- Source: drugdu
- 177
- August 20, 2025
Seven blood metabolites associated with excessive daytime sleepiness

Mass General Brigham researchers identified seven molecules in the blood linked to excessive daytime sleepiness, including factors related to diet and hormones. Approximately one in three Americans reports experiencing overwhelming drowsiness during the day-a condition known as excessive daytime sleepiness (EDS). EDS is linked to an increased risk of serious conditions such as cardiovascular disease, obesity, and diabetes. A new study led by investigators from Mass General Brigham and Beth Israel Deaconess Medical Center identifies several molecules in the blood, known as metabolites, that are linked to EDS. Findings suggest that risk of the condition may be influenced by both internal body processes, such as hormone levels, and external factors such as diet. Results are published in Lancet eBioMedicine. “Our study suggests diet and genetics may play an important role in EDS. As we learn what’s happening biologically, we are beginning to understand how and why EDS occurs, the early ...
- Source: drugdu
- 140
- August 20, 2025
Acetaminophen Linked To Autism/ADHD, Evidence Review Argues

By Dennis Thompson HealthDay ReporterTUESDAY, Aug. 19, 2024 (HealthDay News) — Taking acetaminophen while pregnant might increase a child’s risk of autism or ADHD, a new evidence review says. Analysis of 46 prior studies involving more than 100,000 participants found “strong evidence” that prenatal exposure to acetaminophen could increase the risk of developmental brain disorders like autism and ADHD, researchers reported Aug. 13 in the journal BMC Environmental Health. “Our findings show that higher-quality studies are more likely to show a link between prenatal acetaminophen exposure and increased risks of autism and ADHD,” said lead researcher Diddier Prada, an assistant professor of population health science and policy at the Icahn School of Medicine at Mount Sinai in New York City. This potential link could explain the ongoing surge in developmental disorders among children, the research team said. “As acetaminophen has become the recommended pain reliever for pregnant mothers, the rates ...
- Source: drugdu
- 151
- August 20, 2025
【EXPERT Q&A】Why are glucocorticoids (such as prednisone and deflazacort) the standard therapeutic drugs for Duchenne Muscular Dystrophy (DMD)?

Drugdu.com expert’s response: Glucocorticoids (such as prednisone and deflazacort) are the standard therapeutic drugs for Duchenne muscular dystrophy (DMD), primarily due to their well-established efficacy in delaying disease progression, improving motor function, and prolonging survival. Their mechanisms of action also align closely with the pathological features of DMD. Below is a detailed analysis of the reasons: The only disease-modifying drugs validated by evidence-based medicine Prolonged motor capacity: Multiple studies have demonstrated that glucocorticoids significantly delay the decline in motor function in DMD patients. For example: Children treated with prednisone exhibit superior muscle strength compared to untreated counterparts, with independent walking duration extended by over three years. Deflazacort treatment delays the age at which children lose ambulation by 1.4-2.5 years, increases the 6-minute walk distance, and improves pulmonary function. Delayed complications: Glucocorticoids reduce the risk of scoliosis (11.6% in the treatment group vs. 33.2% in the untreated group), postpone the onset ...
- Source: drugdu
- 205
- August 20, 2025
Tianfeng Securities has given Oulin Bio an “buy” rating. The supply of tetanus vaccine continues to increase, and the Staphylococcus aureus vaccine is about to enter the harvest period

Tianfeng Securities released a research report on August 18th, giving Oulin Bio (688319.SH, latest price: 23.99 yuan) an “overweight” rating. The main reasons for the rating include: 1) The adsorbed tetanus vaccine has been continuously increasing in supply, and the market size has gradually expanded; 2) The research and development progress of Staphylococcus aureus vaccine is leading globally, and the future market prospects are broad. 3) The Helicobacter pylori vaccine has obtained the approval for Phase 1 clinical trials in Australia. Risk Warning: Risk of R&D investment, risk of failure in the development of in-progress products, risk of commercialization not meeting expectations, risk of leakage of core technologies, risk of stock price fluctuations.
- Source: drugdu
- 91
- August 19, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.